The NDA is based on the results of the Phase 3 Clarity AD study and the Phase 2b clinical study, which demonstrated that lecanemab treatment showed a reduc...
During the conference’s poster session, OliX revealed preclinical study results of OLX702A, addressing key mechanisms involved in NASH and obesity. T...
"Hot flashes as a result of menopause can be a serious physical burden on women and impact their quality of life," said Janet Maynard, M.D., M.H.S., direct...
NRC Health has been selected by UCHealth to be its partner in building Human Understanding through personalized healthcare solutions and data-driven i...
The co-development of healthPrecision's Medical Brain artificial intelligence (AI) platform at BayCare will be the first time the technology has been a...
Phase II dose-finding trial met primary endpoint after 46 weeks of treatment, representing an important advancement of Boehringer Ingelheim’s cardi...
Increasing localized access can provide faster results for patients while potentially improving patient outcomes Agreement aims to enable greater access...
Pancreatic adenocarcinoma (PDAC) is one of the most deadly forms of cancer, in part due to the majority of diagnoses being late-stage; the five-year surviv...
Two newly published pieces indicate that the ophthalmology community is more broadly embracing myopia control and management, according to global cat...
A study conducted by the Indian Council of Medical Research (ICMR) in collaboration with the Ministry of Health and Family Welfare, Government of India, wh...
Largely driven by increasing incidence of chronic and infectious diseases and growth in biotechnology and pharma industries, the global immunoassay market ...
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tre...
Other Notable Updates: New American College of Radiology® (ACR®) breast cancer screening guidelines now call for all women &mdas...
EG1206A is a biosimilar drug of the second-generation HER2-positive antibody drug Perjeta® (pertuzumab). EG1206A has a unique binding mechanism for HER...
© 2024 Biopharma Boardroom. All Rights Reserved.
